Logo image
RNAi or overexpression: Alternative therapies for Spinocerebellar Ataxia Type 1
Journal article   Peer reviewed

RNAi or overexpression: Alternative therapies for Spinocerebellar Ataxia Type 1

Megan S Keiser, James C Geoghegan, Ryan L Boudreau, Kim A Lennox and Beverly L Davidson
Neurobiology of disease, Vol.56, pp.6-13
08/2013
DOI: 10.1016/j.nbd.2013.04.003
PMCID: PMC4173078
PMID: 23583610

View Online

Abstract

Spinocerebellar Ataxia Type 1 (SCA1) is an autosomal dominant late onset neurodegenerative disease caused by an expanded polyglutamine tract in ataxin-1. Here, we compared the protective effects of overexpressing ataxin-1-like using recombinant AAVs, or reducing expression of mutant ataxin-1 using virally delivered RNA interference (RNAi), in a transgenic mouse model of SCA1. For the latter, we used an artificial microRNA (miR) design that optimizes potency, efficacy and safety to suppress ataxin-1 expression (miS1). Delivery of either ataxin-1-like or miS1 viral vectors to SCA1 mice cerebella resulted in widespread cerebellar Purkinje cell transduction and improved behavioral and histological phenotypes. Our data indicate the utility of either approach as a possible therapy for SCA1 patients. •AAV-expressed human ataxin-1-like improves behavior and histology in SCA1 mice.•Ataxin-1-like interacts with mutant ataxin-1 in vivo.•Prolonged reduction of ataxin-1 via artificial miRNAs rescues SCA1 phenotypes.
Cerebellum Ataxin-1 RNAi Spinocerebellar Ataxia Type 1 Polyglutamine Neurodegeneration AAV miRNA Ataxin-1-like

Details

Logo image